Botulinum Toxin Type A for Poststroke Cricopharyngeal Muscle Dysfunction
|
|
- Maryann Flowers
- 6 years ago
- Views:
Transcription
1 1346 ORIGINAL ARTICLE Botulinum Toxin Type A for Poststroke Cricopharyngeal Muscle Dysfunction Deog Young Kim, MD, PhD, Chang-il Park, MD, PhD, Suk Hoon Ohn, MD, Ja Young Moon, MD, Won Hyuk Chang, MD, MS, Seung-woo Park, MD, PhD ABSTRACT. Kim DY, Park C, Ohn SH, Moon JY, Chang WH, Park S. Botulinum toxin type A for poststroke cricopharyngeal muscle dysfunction. Arch Phys Med Rehabil 2006;87: Objective: To evaluate the therapeutic effectiveness of botulinum toxin type A (BTX-A) in poststroke patients with cricopharyngeal muscle dysfunction. Design: Before-after trial. Setting: University hospital. Participants: Eight poststroke patients. Intervention: BTX-A injection into the cricopharyngeal muscle under endoscope guidance for poststroke cricopharyngeal muscle dysfunction. Main Outcome Measures: Clinical symptom score, disability rating scale for swallowing impairment, videofluoroscopic swallowing study, and upper esophageal sphincter (UES) manometry. Results: Clinical symptom score, disability rating scale for swallowing impairment, residue in piriform sinus, and UES pressure were all significantly improved at 2 weeks after BTX-A injection compared with evaluations before injection (P.05). The effects on the clinical symptom score and disability rating scale for swallowing impairment continued to be significantly improved to 12 weeks after injection (P.05). However, the residue in piriform sinus and the UES pressure at 12 weeks postinjection were reduced compared with beforeinjection evaluations; these results were not significant. The pharyngeal transit time was not changed after injection. There were no side effects observed in the patients studied. Conclusions: The results of the present study suggest that BTX-A injection may be an effective and safe treatment in patients with poststroke cricopharyngeal muscle dysfunction. Key Words: Botulinum toxin type A; Dysphagia; Pharyngeal muscles; Rehabilitation; Stroke by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation THE PRESENCE OF DYSPHAGIA has been reported to be as high as 30% to 45% among poststroke patients. 1 Dysphagia is associated with increased mortality, increased length of hospital stay, and a decreased level of functional outcome. 1 From the Department and Research Institute of Rehabilitation Medicine (Kim, C Park, Ohn, Moon, Chang) and Department of Internal Medicine (S Park), Yonsei University College of Medicine, Seoul, South Korea. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the author(s) or upon any organization with which the author(s) is/are associated. Reprint requests to Suk Hoon Ohn, MD, Rehabilitation Hospital, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul, , South Korea, myeom@korea.com /06/ $32.00/0 doi: /j.apmr Common swallowing impairments associated with stroke are reduced lingual control, reduced pharyngeal peristalsis, delayed swallowing reflex, and cricopharyngeal muscle dysfunction. 2 The cricopharyngeal muscle acts as a muscular sling at the pharyngoesophageal junction, forming the upper esophageal sphincter (UES). The cricopharyngeal muscle normally remains in a contracted state and relaxes during swallowing. Incoordination or hypertonus of the cricopharyngeal muscle may lead to a range of symptoms including dysphagia and aspiration. Frequently, cricopharyngeal muscle dysfunction is caused by neuromuscular diseases or postoperative changes; however, the etiology remains unknown in a considerable number of cases. 3 Cricopharyngeal muscle dysfunction has been identified in 5.7% of patients with neurologic disorder, 4.9% of patients with head and neck or esophageal tumors, and 8.9% of patients with other medical problems. 4 Bougienage and endoscopic or transcervical cricopharyngeal myotomy have been suggested to lower the resting pressure of the cricopharyngeal muscle. However, the effect of these procedures has been debated, and they are associated with a variety of complications. 5,6 Botulinum toxin type A (BTX-A), synthesized from the bacillus Clostridium botulinum, is a neurotoxin that blocks neuromuscular transmission by inhibition of acetylcholine release at the presynaptic cholinergic nerve terminals. It has been found to have therapeutic value in patients with a variety of conditions characterized by muscle hyperactivity and spasticity For the treatment of cricopharyngeal muscle dysfunction, BTX-A was used for the first time by Schneider et al 11 in Since Schneider s report, there have been many studies reporting on BTX-A use to treat patients with cricopharyngeal muscle dysfunction Previous studies, however, included various etiologies of cricopharyngeal muscle dysfunction, including stroke. Haapaniemi et al 13 studied 2 stroke patients, 1 with lesions in the brainstem and the other with lesions in the middle cerebral artery. The stroke patient with brainstem lesions was able to eat quite normally for 10 months after the injection. The stroke patient with middle cerebral artery lesions was able to tolerate oral feeding for 2 months. Ahsan et al 14 studied 2 stroke patients; 1 patient was not improved after injection, and the other patient was improved for 2 months and then relapsed. Alberty et al 15 studied 1 brainstem stroke patient, whose dysphagia symptom was not improved after injection. Shaw and Searl 16 studied 2 stroke patients. In 1 patient, subjective symptom relief continued for 14 months; however, there was no objective measure of the improvement. Murry et al 17 studied 13 patients including 6 stroke patients and reported the efficacy of BTX-A. These studies focused on patients with a variety of causes of cricopharyngeal muscle dysfunction, and the effect of BTX-A in a sample of only stroke patients has not yet been established. Therefore, the aim of this study was to evaluate the therapeutic effect of BTX-A injection on the cricopharyngeal muscle for poststroke patients with cricopharyngeal muscle dysfunction.
2 BOTULINUM TOXIN FOR CRICOPHARYNGEAL MUSCLE DYSFUNCTION, Kim 1347 Patient No. Table 1: General Characteristics of Subjects Age (y) Sex Diagnosis METHODS Duration From Onset (mo) Feeding Method 1 66 M Cerebellar infarction 8 NG tube 2 56 M Cerebellar infarction 3 NG tube 3 68 F Pontine hemorrhage 2 NG tube 4 53 M Lateral medullary 7 NG tube infarction 5 65 M Cerebellar infarction 8 Oral 6 46 F Posterior cerebral 5 Oral artery infarction 7 65 M Lateral medullary 4 PEG tube infarction 8 64 F Pontine hemorrhage 3 NG tube Abbreviations: F, female; M, male; NG tube, nasogastric tube; PEG tube, percutaneous endoscopic gastrostomy tube. Participants Eight stroke patients (5 men, 3 women) with cricopharyngeal muscle dysfunction were recruited for this study after we obtained informed consent (table 1). This study was approved by the institutional review board of our institute. The mean duration from stroke onset was 5.0 months (range, 2 8mo). The diagnosis of stroke in all participants was confirmed by magnetic resonance imaging, and the following abnormalities were found: cerebellar infarction (n 3), pontine hemorrhage (n 2), lateral medullary infarction (n 2), and posterior cerebral artery infarction (n 1). Cricopharyngeal muscle dysfunction was confirmed by a videofluoroscopic swallowing study (VFSS). The severity of dysphagia was classified by the clinical symptom score. 15 Clinical symptom scores for all patients were equal to or more than 7; therefore, all patients were classified as severe. Five patients were being nourished by a nasogastric tube and 1 patient by a percutaneous endoscopic gastrostomy tube. Two patients were eating by mouth. Before the BTX-A injection, we followed up with all patients; they did not have improved dysphagia symptoms, even after intensive interventions including the Mendelsohn maneuver, neck rotation to the affected side, and bougienage for at least 2 weeks. One of the 8 patients, a 65-year-old man with a cerebellar infarct, was withdrawn because of another cerebral infarct at 3 weeks after the BTX-A injection; however, his dysphagia was improved (table 2). Therefore, 7 patients were available for the remainder of the study. Procedure A standard medical history and physical, neurologic, and otolaryngologic examination were provided for each patient. The clinical symptom score and disability rating scale for swallowing impairment 11 were assessed to determine the severity of dysphagia before the injection and at the 2nd, 4th, and 12th weeks after injection. The clinical symptom score consisted of 4 categories: tolerated food consistency (score, 0 3), relative duration of food intake (score, 0 2), requirement of additional swallows for emptying the hypopharynx (score, 0 2), and clinical signs of aspiration (score, 0 3). According to the sum of each category, dysphagia was classified as mild (score, 1 3), moderate (score, 4 6), or severe (score, 7 10). 15 In addition, we used the disability rating scale for swallowing impairment. The severity of dysphagia was rated on a scale of 0 to 4. The disability rating scale for swallowing impairment includes a score of 0 for normal function and a patient without complaint, a score of 1 for no functional impairment but subjective dysphagia when swallowing solid and/or liquid foods, a score of 2 for mild functional impairment for solid and/or liquid foods, a score of 3 for marked disability with moderate aspiration, and a score of 4 for severe functional impairment with complete inability to swallow, a consideration of aspiration or pneumonia. In addition, body weight was recorded before injection and at the 2nd, 4th, and 12th weeks after injection. VFSS and UES manometry were performed before injection and at the 2nd and 12th weeks after injection. After the VFSS was completed, 2 physiatrists analyzed the results. For the VFSS, the test liquid was prepared from 200mL of water and 40mL of gastrograffin. a The patients were positioned upright for an anteroposterior view, and the amount of piriform sinus residue was measured by 15mL of test liquid 8 times. Next, the patients were positioned upright for a lateral view, and the pharyngeal transit time was measured 8 times. The residue from the piriform sinus was assessed by the remaining amount of liquid in the piriform sinus that did not pass through the cricopharyngeal muscle. In addition, the pharyngeal transit time was assessed to examine whether injected BTX-A affected other pharyngeal muscles. The amount of piriform sinus residue after swallowing was classified into 4 grades (grade 0, no residue; grade 1, 10% of the width of piriform sinus in the VFSS; grade 2, 10% 50% of the width; grade 3, 50% of the width). 18 Pharyngeal transit time was defined as the time for the liquid to pass from the onset of hyoid bone elevation to cessation of its motion. 19 To determine the precise timing, a video counter timer was superimposed on a video screen at a rate of 30 frames per second. Patient No. Table 2: Change at Each Evaluation After BTX-A Injection Clinical Symptom Score Disability Rating Scale Score Weight (kg) Residue (grade) UES Pressure (mmhg) T0 T1 T2 T3 T0 T1 T2 T3 T0 T1 T2 T3 T0 T1 T3 T0 T1 T * 7 5 ND ND 2 2 ND ND ND ND 3 1 ND ND Abbreviations: ND, no data; T0, before injection; T1, 2nd week after injection; T2, 4th week after injection; T3, 12th week after injection. *Patient 5 was withdrawn because of a newly developed cerebral infarction at 3 weeks after BTX-A injection.
3 1348 BOTULINUM TOXIN FOR CRICOPHARYNGEAL MUSCLE DYSFUNCTION, Kim We then measured the average pharyngeal transit time from the 8 trials. UES manometry with 6 channels b was performed to obtain the resting pressure of the cricopharyngeal muscle. We used the station pull-through technique. This procedure was performed by an internal medicine physician who specialized in UES manometry. A manometric catheter was advanced into the stomach and then was advanced cephalad while the pressure was recorded. The maximal pressure at the first high-pressure zone was defined as the pressure of the lower esophageal sphincter. After further advancement of catheter, the second maximal pressure was defined as the pressure of the UES. BTX-A (Botox) was obtained as a freeze-dried lyophilized preparation, and 100U of BTX-A were dissolved into 2.0mL of 0.9% sterile saline. This diluted solution, equivalent to 100U of BTX-A, was injected with a small butterfly cannula under the guidance of a flexible endoscope. We selected 3 injection sites: the posterior part and both lateral sides of the cricopharyngeal muscle; these sites were chosen for easy identification and avoidance of laryngeal side effects. The amount of injected BTX-A at each portion was 50U for the posterior site and 25U each at the lateral sites. We used the nonparametric Wilcoxon test of SPSS c for each parameter. We compared the postinjection clinical symptom score, disability rating scale for swallowing impairment, body weight, residue in the piriform sinus, pharyngeal transit time, and UES pressure with the same measures used at baseline. RESULTS Clinical Score The clinical symptom score and disability rating scale for swallowing impairment at 2 weeks after BTX-A injection improved significantly compared with the baseline measures (figs 1, 2). The clinical symptom score improved from to , and the disability rating scale score for swallowing impairment improved from to After 4 and 12 weeks of follow-up, the clinical symptom score and disability rating scale score for swallowing impairment showed significant improvement compared with baseline Fig 2. Change in disability rating scale score for swallowing impairment after BTX-A injection. *Significant at P<.05. measures. The clinical symptom scores at 4 and 12 weeks were and , and the disability rating scale scores for swallowing impairment at 4 and 12 weeks were and , respectively. The body weights recorded at baseline and at 2, 4, and 12 weeks after injection were kg, kg, kg, and kg, respectively (fig 3). The body weight at 4 and 12 weeks after injection improved significantly compared with baseline measures. VFSS Findings The grade of residue at 2 weeks after the BTX-A injection decreased significantly compared with the baseline (fig 4). The grade of residue changed from to The grade Fig 1. Change in clinical symptom score after BTX-A injection. Abbreviation: T, time. *Significant at P<.05. Fig 3. Change in body weight after BTX-A injection. *Significant at P<.05.
4 BOTULINUM TOXIN FOR CRICOPHARYNGEAL MUSCLE DYSFUNCTION, Kim 1349 Fig 4. Change of residue in piriform sinus after BTX-A injection. *Significant at P<.05. Fig 6. Change of UES pressure after BTX-A injection. *Significant at P<.05. of the residue at 12 weeks after injection was ; this was reduced compared with the baseline measures and was not significant (P.109). However, the pharyngeal transit time did not change after injection (fig 5). Resting UES Pressures The UES pressure at 2 weeks after BTX-A injection decreased significantly compared with the baseline. The UES pressure changed from to mmHg (fig 6). The UES pressure at 12 weeks postinjection was mmHg; this was reduced compared with baseline measures and was not significant (P.310). Complications There were no side effects observed such as pharyngeal tears, vocal cord palsy, or other systemic effects. Fig 5. Change of pharyngeal transit time (PTT) after BTX-A injection. DISCUSSION In this study, we used BTX-A in a group of stroke patients with cricopharyngeal muscle dysfunction and evaluated the effects not only subjectively but also objectively. For the subjective evaluation, the clinical symptom score and disability rating scale score for swallowing impairment were used. For these 2 evaluations, dysphagia symptoms were significantly improved and continued to be improved for 12 weeks postinjection. In addition, VFSS and UES manometry were used as objective diagnostic tools for cricopharyngeal muscle dysfunction measures. The real-time demonstration of swallowing with VFSS is the most sensitive method for visualizing cricopharyngeal muscle dysfunction. 20 We could observe the total swallowing process and examine the residue of piriform sinus. To obtain quantitative information on cricopharyngeal muscle dysfunction, we used UES manometry. UES manometry is the only method that can quantify the muscle tone of the cricopharyngeal muscle. Previous studies have used manometry for objective measurement of cricopharyngeal muscle tone. 16,21 However, because of the lack of normative data and technical difficulties, the use of manometry alone for the assessment of UES function has been limited. 22 In previous research, the UES pressures did not correlate with the severity of cricopharyngeal muscle dysfunction in patients. 14 Therefore, for a precise evaluation of cricopharyngeal muscle dysfunction, a combined study of VFSS and UES manometry is essential. In our study, the results of VFSS and manometry differed somewhat from the clinical symptom score and disability rating scale for swallowing impairment. The residue from the piriform sinus and the UES pressure were improved at 2 weeks after injection. These improved findings continued 12 weeks after injection; however, the values were not statistically significant. In addition, patients body weights increased after BTX-A injection. This finding is likely due to an increase of oral intake as the swallowing problem was settled. In this study, the 2 patients with little improvement after the injection had lateral medullary infarction. Patient 7 was a 65-year-old man whose dysphagia symptom improved at the evaluation 2 weeks after BTX-A injection but then worsened after that time (see table 2). Patient 4 was a 53-year-old man whose dysphagia symptom did not change during the follow-up period. Another report also showed that cricopharyngeal mus-
5 1350 BOTULINUM TOXIN FOR CRICOPHARYNGEAL MUSCLE DYSFUNCTION, Kim cle dysfunction was worse in a patient with stroke lesion in the brainstem. Alberty et al 15 examined 10 patients for the effects of BTX-A on cricopharyngeal muscle dysfunction. The causes of cricopharyngeal muscle dysfunction were brainstem infarction in 1 patient, polymyositis in 1 patient, and idiopathic in the remaining 8 patients. After the BTX-A injection, the patient with the brainstem infarction and 1 with idiopathic cricopharyngeal muscle dysfunction were found to have the amount of barium retention by VFSS unchanged. The ineffectiveness of the BTX-A injection may be explained by the following. The first possible cause of ineffectiveness might be the involvement of the bulbar swallowing center; that made the swallowing problem a lower motoneuron lesion. The lateral medullary infarction inflicted direct trauma on the swallowing center and the nuclei of cranial nerves XI and X. If the medullary lesion involves the postnucleus neural tract, the relaxation problem of the cricopharyngeal muscle appears as a lower motoneuron lesion. Therefore, BTX-A injection might not be suitable to resolve cricopharyngeal muscle dysfunction in such a case. Another possible explanation might be that the pharyngeal phase of swallowing is reflexogenic; for the successful pharyngeal phase, all reflex pathways from afferent input to efferent output should be intact. These reflex pathways consist of glossopharyngeal and vagal afferents derived from pharyngeal mucosa and hyoid bone elevation by the mylohyoid, anterior belly of digastric, hyoglossus, and geniohyoid muscles. After hyoid bone elevation, reflexogenic glottic closure and UES opening occur in sequence. If any problem in this pathway is not improved, the pharyngeal phase will not be restored, even if BTX-A decreases the cricopharyngeal muscle tone. BTX-A may influence only the hypertonus cricopharyngeal muscle in upper motoneuron disorders and not the pharyngeal swallowing reflex. Therefore, the effectiveness of BTX-A injection at the cricopharyngeal muscle depends on the pathophysiology of the brain lesion. It may be difficult to predict the effectiveness of BTX-A injection for cricopharyngeal muscle dysfunction treatment by medical history, VFSS, UES manometry, and other measures commonly used. The BTX-A dose used and the effective duration vary depending on the injected site and muscle In the case of cricopharyngeal muscle dysfunction, the optimal dose and the effective duration continue to be evaluated. Shaw and Searl 16 suggested that higher doses may result in a longer duration of action. However, they had a good result with a small dose, 50U. In our study, 100U of BTX-A (Botox) were used. This dose was 1.6 to 2.4U/kg in our patients, and was a larger dose compared with previous studies, where use of 10 to 50U of BTX-A has been reported With 100U of BTX-A, we found that the duration of the effect continued for 12 weeks. In our study, there were no side effects or other systemic effects, even though we used a higher dose of BTX-A than in prior studies. The complications reported with BTX-A injection have been pharyngeal tear, transient vocal cord palsy, and urinary retention for 2 days. 13,16 However, previous studies 7,11,14,15 also reported that BTX-A injection in the cricopharyngeal muscle was comparatively well tolerated without serious side effects. We examined the pharyngeal transit time by VFSS to examine whether the injected BTX-A spread from the cricopharyngeal muscle. If BTX-A spreads out of the cricopharyngeal muscle, the pharyngeal transit time may have been delayed because of resulting pharyngeal muscle palsy. In our study, pharyngeal transit time did not change in any of the patients after BTX-A injection. Therefore, we could examine only the cricopharyngeal muscle function without other pharyngeal involvement. The BTX-A dose of 100U dissolved in 2.0mL of 0.9% sterile saline was safe and did not have other pharyngeal effects. There are several limitations to this study. First, this was not a case-control study. Participants in this study were patients whose cricopharyngeal muscle dysfunction symptoms had not been definitely improved despite intensive interventions for more than 2 weeks. The participants were all treated by BTX-A injection. Therefore, we could not compare the BTX-A injection group with a group without BTX-A injection. Second, 5 participants in this study were subacute patients who developed stroke within 6 months. Although the patients cricopharyngeal muscle dysfunction symptom had not improved despite other interventions, the possible effect of spontaneous recovery cannot be excluded completely. Finally, the number of subjects was small. These limitations suggest the need for additional study to confirm our findings. Our study followed up patients with both subjective and objective evaluations for a longer time than has been reported in previous studies. Despite continuously improved dysphagia symptoms by the clinical symptom score and the disability rating scale score for swallowing impairment, a longer evaluation period would give us more information about the maintenance of BTX-A for cricopharyngeal muscle dysfunction treatment in stroke patients. Our findings show the effectiveness of BTX-A injection for the treatment of cricopharyngeal muscle dysfunction in pure stroke patients. This is the first study of pure stroke patients with cricopharyngeal muscle dysfunction. BTX-A injection at the cricopharyngeal muscle is a safe and effective alternative treatment even during the acute period. However, if a lesion appears to be localized in the swallowing center of the medulla, more exact neurologic examination should be performed before BTX-A injection is considered. CONCLUSIONS This study examined the effect of BTX-A for the treatment of cricopharyngeal muscle dysfunction in stroke patients. After BTX-A injection, dysphagia symptoms improved, and this was shown subjectively and objectively. The clinical symptom score, disability rating scale score for swallowing impairment, and body weight continued to be significantly improved until 12 weeks after injection. The residue in the piriform sinus and the UES pressure were significantly improved for 2 weeks after injection, and the improvements continued at 12 weeks after injection; however, these findings were not significant. None of the patients reported side effects. Therefore, BTX-A injection may be an effective and safe treatment for patients with poststroke cricopharyngeal muscle dysfunction. References 1. Horner J, Massey EW, Brazer SR. Aspiration in bilateral stroke patients: a validation study. Neurology 1993;43: Veis SL, Logemann JA. Swallowing disorders in persons with cerebrovascular accident. Arch Phys Med Rehabil 1985;66: Cruse JP, Edwards DA, Smith JF, Wyllie JH. The pathology of cricopharyngeal dysphagia. Histopathology 1972;3: Baredes S, Shah CS, Kaufman R. The frequency of cricopharyngeal dysfunction on videofluoroscopic swallowing studies in patients with dysphagia. Am J Otol 1997;18: Ellis FH Jr, Crozier RE. Cervical esophageal dysphagia: indications for and results of cricopharyngeal myotomy. Ann Surg 1981;194: Ross ER, Green R, Auslander MO, Biller HF. Cricopharyngeal myotomy: management of cervical dysphagia. Otolaryngol Head Neck Surg 1982;90:
6 BOTULINUM TOXIN FOR CRICOPHARYNGEAL MUSCLE DYSFUNCTION, Kim Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 1995;18: Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 1990;12: Blitzer A, Brin MF, Fahn S, Lovelace RE. Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope 1988;98: Graham HK, Aoki KR, Autti-Ramo I, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000;11: Schneider I, Thumfart WF, Pototschnig C, Eckel HE. Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: introduction of a new, noninvasive method. Ann Otol Rhinol Laryngol 1994;103: Blitzer A, Mitchell FB. Use of botulinum toxin for diagnosis and management of cricopharyngeal achalasia. Otolaryngol Head Neck Surg 1997;116: Haapaniemi JJ, Laurikainen EA, Pulkkinen J, Marttila RJ. Botulinum toxin in the treatment of cricopharyngeal dysphagia. Dysphagia 2001;16: Ahsan SF, Meleca RJ, Dworkin JP. Botulinum toxin injection of the cricopharyngeus muscle for the treatment of dysphagia. Otolaryngol Head Neck Surg 2000;122: Alberty J, Oelerich M, Ludwig K, Hartmann S, Stoll W. Efficacy of botulinum toxin A for treatment of upper esophageal sphincter dysfunction. Laryngoscope 2000;110: Shaw GY, Searl JP. Botulinum toxin treatment for cricopharyngeal dysfunction. Dysphagia 2001;16: Murry T, Wasserman T, Carrau RL, Castillo B. Injection of botulinum toxin A for the treatment of dysfunction of the upper esophageal sphincter. Am J Otolaryngol 2005;26: Han TR, Paik NJ, Park JW. Quantifying swallowing function after stroke: a functional dysphagia scale based on videofluoroscopic studies. Arch Phys Med Rehabil 2001;82: McConnel FM, Cerenko D, Jackson RT, Guffin TN Jr. Timing of major events of pharyngeal swallowing. Arch Otolaryngol Head Neck Surg 1988;114: Sonies BC, Baum BJ. Evaluation of swallowing pathophysiology. Otolaryngol Clin North Am 1988;21: Brant CQ, Siqueira ES, Ferrari AP Jr. Botulinum toxin for oropharyngeal dysphagia: case report of flexible endoscope-guided injection. Dis Esophagus 1999;12: Kelly JH. Use of manometry in the evaluation of dysphagia. Otolaryngol Head Neck Surg 1997;116: Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN. Treatment of achalasia with intrasphincteric injection of botulinum toxin. A pilot trial. Ann Intern Med 1994;121: Pasricha PJ, Ravich WJ, Hendrix TR. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995;332: Pasricha PJ, Rai R, Ravich WJ, Hendrix TR, Kalloo AN. Botulinum toxin for achalasia: long term outcome and predictors of response. Gastroenterology 1996;110: Ferrari AP, Siqueira ES, Brant CQ. Treatment of achalasia in Chagas disease with botulinum toxin. N Engl J Med 1995;332: Suppliers a. Schering-Plough SA, Cantabria, 2. Edificio Amura, Alcobendas, Madrid, Spain. b. Polygraf ID; Medtronic, 710 Medtronic Pkwy, Minneapolis, MN c. Version 12.0; SPSS Inc, 233 S Wacker Dr, 11th Fl, Chicago, IL
TREATMENT OF DYSPHAGIA IN PATIENTS AFTER STROKE IN ESTONIA
TREATMENT OF DYSPHAGIA IN PATIENTS AFTER STROKE IN ESTONIA ANNE URIKO SPORTS MEDICINE AND REHABILITATION CLINIG OF TARTU UNIVERSITY HOSPITAL 17.09.2010 DYSPHAGIA DIFFICULTY MOVING FOOD FROM MOUTH TO STOMACH
More informationEndoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia Difficulty
More informationTitle. manometry system. Author(s) Takahashi, Haruo. Auris Nasus Larynx, 37(5), pp Issue Date
NAOSITE: Nagasaki University's Ac Title Author(s) Citation Evaluation of swallowing pressure i sclerosis before and after cricopha manometry system. Takasaki, Kenji; Umeki, Hiroshi; En Takahashi, Haruo
More informationBotox. Botox (onabotulinum toxin A) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.01 Subject: Botox Page: 1 of 10 Last Review Date: November 30, 2018 Botox Description Botox (onabotulinum
More informationBOTOX. Description. Section: Prescription Drugs Effective Date: January 1, 2013 Subsection: CNS Original Policy Date: December 7, 2011
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.12.01 Subject: Botox Page: 1 of 6 Last Review Status/Date: December 6, 2012 BOTOX Description Botox (onabotulinum
More informationMain Aspects of the Management of Neurogenic Dysphagia
Main Aspects of the Management of Neurogenic Dysphagia Mario Prosiegel/München German Society of Neurology (DGN) prosiegel@t-online.de DYSPHAGIA October 8-10, 2015 Pavia, Italy Overview Diagnosis Causal
More informationImmediate effectiveness of balloon dilatation therapy for patients with dysphagia due to cricopharyngeal dysfunction
87 Japanese Journal of Comprehensive Rehabilitation Science (2014) Original Article Immediate effectiveness of balloon dilatation therapy for patients with dysphagia due to cricopharyngeal dysfunction
More informationTHE CLINICAL USE OF BOTULINUM TOXIN IN THE TREATMENT OF MOVEMENT DISORDERS, SPASTICITY, AND SOFT TISSUE PAIN
THE CLINICAL USE OF BOTULINUM TOXIN IN THE TREATMENT OF MOVEMENT DISORDERS, SPASTICITY, AND SOFT TISSUE PAIN Spasmodic torticollis (cervical dystonia), blepharospasm, and writer s cramp are specific types
More informationDysphagia and Swallowing. Jan Adams, DNP, MPA, RN and Karen Kern
Dysphagia and Swallowing Jan Adams, DNP, MPA, RN and Karen Kern Scope of the Problem and Incidence 15 million people in the US have some form of Dysphagia. Every year, 1 million people are diagnosed with
More informationApplied physiology. 7- Apr- 15 Swallowing Course/ Anatomy and Physiology
Applied physiology Temporal measures: Oral Transit Time (OTT) Pharyngeal Delay Time (PDT) Pharyngeal Transit Time (PTT) Oropharyngeal Swallowing Efficiency Score (OPSE score) 7- Apr- 15 Swallowing Course/
More informationBotox. Botox (onabotulinum toxin A) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.01 Subject: Botox Page: 1 of 8 Last Review Date: September 15, 2017 Botox Description Botox (onabotulinum
More informationcopyrighted material by PRO-ED, Inc.
CONTENTS Preface xi Chapter 1 Introduction: Definitions and Basic Principles of Evaluation and Treatment of Swallowing Disorders Signs and Symptoms of Dysphagia Screening: Identifying the Patient at High
More informationSUPER-SUPRAGLOTTIC SWALLOW IN IRRADIATED HEAD AND NECK CANCER PATIENTS
SUPER-SUPRAGLOTTIC SWALLOW IN IRRADIATED HEAD AND NECK CANCER PATIENTS Jeri A. Logemann, PhD, 1 Barbara Roa Pauloski, PhD, 1 Alfred W. Rademaker, PhD, 2 Laura A. Colangelo, MS 2 1 Department of Communication
More informationDaniels SK & Huckabee ML (2008). Dysphagia Following Stroke. Muscles of Deglutition. Lateral & Mesial Premotor Area 6. Primary Sensory
An Overview of Dysphagia in the Stroke Population Stephanie K. Daniels, PhD Michael E. DeBakey VA Medical Center PM & R, Baylor College of Medicine Communication Sciences and Disorders, University of Houston
More informationDepartment of Occupational Therapy, Graduate School of Yonsei University, Wonju, Korea
Original Article Ann Rehabil Med 2014;38(5):612-619 pissn: 2234-0645 eissn: 2234-0653 http://dx.doi.org/10.5535/arm.2014.38.5.612 Annals of Rehabilitation Medicine Cutoff Value of Pharyngeal Residue in
More informationSwallowing Disorders and Their Management in Patients with Multiple Sclerosis
National Multiple Sclerosis Society 733 Third Avenue New York, NY 10017-3288 Clinical Bulletin Information for Health Professionals Swallowing Disorders and Their Management in Patients with Multiple Sclerosis
More informationCombined Experience of Two European Centers
Minimally Invasive Surgery for Achalasia: Combined Experience of Two European Centers Garzi A, Valla JS*, Molinaro F, Amato G, Messina M. Unit of Pediatric Surgery, University of Siena (Italy) *Lenval
More informationOro-pharyngeal and Esophageal Motility and Dysmotility John E. Pandolfino, MD, MSci
Oro-pharyngeal and Esophageal Department of Medicine Feinberg School of Medicine Northwestern University 1 Oro-pharyngeal and Esophageal Motility Function: Oropharynx Transfer food Prevent aspiration Breathing
More informationTHORACIC SURGERY: Dysphagia. Dr. Robert Zeldin Dr. John Dickie Dr. Carmine Simone. Thoracic Surgery Toronto East General Hospital
THORACIC SURGERY: Dysphagia Dr. Robert Zeldin Dr. John Dickie Dr. Carmine Simone Thoracic Surgery Toronto East General Hospital Objectives Definitions Common causes Investigations Treatment options Anatomy
More informationAchalasia: Classic View
Achalasia: Dilate, Botox, Knife or POEM Prateek Sharma, MD Kansas University School of Medicine Achalasia: Classic View 1 Diagnosis of Achalasia Endoscopy may be normal in as many as 44% Upper GI series
More informationRole of Laryngeal Movement and Effect of Aging on Swallowing Pressure in the Pharynx and Upper Esophageal Sphincter
The Laryngoscope Lippincott Williams & Wilkins, Inc., Philadelphia 2000 The American Laryngological, Rhinological and Otological Society, Inc. Role of Laryngeal Movement and Effect of Aging on Swallowing
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/32744 holds various files of this Leiden University dissertation Author: Heemskerk, Anne-Wil Title: Dysphagia in Huntington s disease Issue Date: 2015-04-15
More informationSurgical aspects of dysphagia
Dysphagia Why is dysphagia important? Surgery Surgical aspects of dysphagia Adrian P. Ireland aireland@eircom.net Academic RCSI Department of Surgery, Beaumont Hospital Why important Definitons Swallowing
More informationNEUROMUSCULAR ELECTRICAL AND THERMAL-TACTILE STIMULATION FOR DYSPHAGIA CAUSED BY STROKE: A RANDOMIZED CONTROLLED TRIAL
J Rehabil Med 2009; 41: 174 178 ORIGINAL REPORT NEUROMUSCULAR ELECTRICAL AND THERMAL-TACTILE STIMULATION FOR DYSPHAGIA CAUSED BY STROKE: A RANDOMIZED CONTROLLED TRIAL Kil-Byung Lim, MD, PhD 1, Hong-Jae
More informationTracheoesophageal voice (TEV) with voice prosthesis
Braz J Otorhinolaryngol. 2009;75(2):182-7. ORIGINAL ARTICLE Computerized manometry use to evaluate spasm in pharyngoesophageal segment in patients with poor tracheoesophageal speech before and after treatment
More information15/11/2011. Swallowing
Swallowing Swallowing starts from placement of the food in the mouth and continues until food enters the stomach. Dysphagia: any difficulty in moving food from mouth to stomach. Pharynx is shared for both
More informationThe Clinical Swallow Evaluation: What it can and cannot tell us. Introduction
The Clinical Swallow Evaluation: What it can and cannot tell us Debra M. Suiter, Ph.D., CCC-SLP, BCS-S Director, Voice & Swallow Clinic Associate Professor, Division of Communication Sciences & Disorders
More informationEffects of a Sour Bolus on Oropharyngeal Swallowing Measures in Patients With Neurogenic Dysphagia
Journal of Speech and Hearing Research, Volume 38, 556-563, June 1995 Effects of a Sour Bolus on Oropharyngeal Swallowing Measures in Patients With Neurogenic Dysphagia Jeri A. Logemann Barbara Roa Pauloski
More informationScottish Medicines Consortium
Scottish Medicines Consortium clostridium botulinum neurotoxin type A, 100 unit powder for solution for injection (Xeomin ) No. (464/08) Merz Pharma UK Ltd 09 May 2008 The Scottish Medicines Consortium
More informationDYSPHAGIA MANAGEMENT IN ACUTE CARE AMANDA HEREFORD, MA, CCC- SLP
DYSPHAGIA MANAGEMENT IN ACUTE CARE AMANDA HEREFORD, MA, CCC- SLP OVERVIEW Decision making re: swallowing in the medically compromised patient Swallow evaluation vs. Nursing Swallow Screening Instrumental
More information2013 Charleston Swallowing Conference
Providing Quality Affordable Continuing Education and Treatment Materials for over 30 years. 2013 Charleston Swallowing Conference Session 9 Bedside Assessment: What Does It Tell You? 10:00 11:30 am Saturday,
More informationDysphagia. A Problem Swallowing Foods or Liquids
Dysphagia A Problem Swallowing Foods or Liquids What Is Dysphagia? If you have a problem swallowing foods or liquids, you may have dysphagia. It has a number of causes. Your doctor can find out what is
More informationInfluence of Dysphagia on Short-Term Outcome in Patients with Acute Stroke
Authors: Shinichiro Maeshima, MD, PhD Aiko Osawa, MD Yasuhiro Miyazaki, MA Yasuko Seki, BA Chiaki Miura, BA Yuu Tazawa, BA Norio Tanahashi, MD Affiliations: From the Department of Rehabilitation Medicine
More informationPharyngeal Effects of Bolus Volume, Viscosity, and Temperature in Patients With Dysphagia Resulting From Neurologic Impairment and in Normal Subjects
Journal of Speech and Hearing Research, Volume 37, 1041-1049, October 1994 Pharyngeal Effects of Bolus Volume, Viscosity, and Temperature in Patients With Dysphagia Resulting From Neurologic Impairment
More informationSwallowing Screen Why? How? and So What? พญ.พวงแก ว ธ ต สก ลช ย ภาคว ชาเวชศาสตร ฟ นฟ คณะแพทยศาสตร ศ ร ราชพยาบาล
Swallowing Screen Why? How? and So What? พญ.พวงแก ว ธ ต สก ลช ย ภาคว ชาเวชศาสตร ฟ นฟ คณะแพทยศาสตร ศ ร ราชพยาบาล Dysphagia in Stroke The incidence of dysphagia after stroke ranging from 23-50% 1 Location
More informationPostoperative swallowing function after posterior fossa tumor resection in pediatric patients
Childs Nerv Syst (2006) 22: 1296 1300 DOI 10.1007/s00381-006-0065-z ORIGINAL PAPER Lisa A. Newman Frederick A. Boop Robert A. Sanford Jerome W. Thompson Carrie K. Temple Christopher D. Duntsch Postoperative
More information34th Annual Toronto Thoracic Surgery Refresher Course
34th Annual Toronto Thoracic Surgery Refresher Course TREATMENT OPTIONS FOR ACHALASIA Dr. Carmine Simone Director, Intensive Care Unit Head, Division of Critical Care Departments of Medicine and Surgery
More informationHemifacial spasm. Parkinson's Disease Center and Movement Disorders Clinic
Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Hemifacial spasm Diagnosis Hemifacial spasm
More informationSwallowing after a Total Laryngectomy
Swallowing after a Total Laryngectomy Diane Longnecker, M.S.,CCC-SLP, BCS-S Baylor Institute for Rehabilitation at Baylor University Medical Center Dallas, TX Disclosure Statement No relevant financial
More informationSwallowing Course (RHS )
Swallowing Course (RHS ) Dr/Mohamed Farahat Ibrahim, M.D., Ph.D. Professor, Consultant Phoniatrician (Communication and Swallowing Disorders) Chairman, Communication and Swallowing Disorders Unit (CSDU)
More informationFeeding and Swallowing Problems in the Child with Special Needs
Feeding and Swallowing Problems in the Child with Special Needs Joan Surfus, OTR/L, SWC Amy Lynch, MS, OTR/L Misericordia University This presentation is made possible, in part, by the support of the American
More informationACHALASIA is a disorder of esophageal motility
774 THE NEW ENGLAND JOURNAL OF MEDICINE March 23, 1995 INTRASPHINCTERIC BOTULINUM TOXIN FOR THE TREATMENT OF ACHALASIA PANKAJ J. PASRICHA, M.D., WILLIAM J. RAVICH, M.D., THOMAS R. HENDRIX, M.D., SAMUEL
More informationPer-oral Endoscopic Myotomy
POEM With the Flexible Scope as a Treatment for Achalasia and Zenker's Diverticulum Abraham Mathew, MD, MSc Professor of Medicine Penn State College of Medicine Penn State Hershey Medical Center Per-oral
More informationTreating Achalasia. When to consider surgery and New options for therapy
Treating Achalasia When to consider surgery and New options for therapy James B. Wooldridge,Jr., MD Ochsner Medical Center Senior Staff Surgeon General, Laparoscopic, and Bariatric Surgery Disclosures
More informationA dysphagia study in patients with sporadic inclusion body myositis (s-ibm)
Neurol Sci (2012) 33:765 770 DOI 10.1007/s10072-011-0814-y ORIGINAL ARTICLE A dysphagia study in patients with sporadic inclusion body myositis (s-ibm) Ken-ya Murata Ken Kouda Fumihiro Tajima Tomoyoshi
More informationManagement of oropharyngeal dysphagia
Management of oropharyngeal dysphagia Course Objectives Know the normal anatomy of swallowing Know the normal physiology of swallowing Enumerate different etiologies of oropharyngeal dysphagia Be able
More informationDuke Masters of Minimally Invasive Thoracic Surgery Orlando, FL. September 17, Session VI: Minimally Invasive Thoracic Surgery: Miscellaneous
Duke Masters of Minimally Invasive Thoracic Surgery Orlando, FL September 17, 2016 Session VI: Minimally Invasive Thoracic Surgery: Miscellaneous NOTES and POEM James D. Luketich MD, FACS Henry T. Bahnson
More informationDiffusion of aniline blue injected into the thyroarytenoid muscle as a proxy for botulinum toxin injection: an experimental study in cadaver larynges
Original Article Int. Arch. Otorhinolaryngol. 2013;17(3):315-320. DOI: 10.7162/S1809-977720130003000012 Diffusion of aniline blue injected into the thyroarytenoid muscle as a proxy for botulinum toxin
More informationClearance mechanisms of the aperistaltic esophagus. The pump-gun hypothesis.
Gut Online First, published on December 14, 2005 as 10.1136/gut.2005.085423 Clearance mechanisms of the aperistaltic esophagus. The pump-gun hypothesis. Radu Tutuian 1, Daniel Pohl 1, Donald O Castell
More informationStage Transition And Laryngeal Closure In Poststroke Patients With Dysphagia
Archived version from NCDOCKS Institutional Repository http://libres.uncg.edu/ir/asu/ Stage Transition And Laryngeal Closure In Poststroke Patients With Dysphagia By: Elizabeth Rachel Oommen Youngsun Kim
More informationDANTROLENE SODIUM IS a muscle relaxant that acts
ORIGINAL ARTICLE Safety of Low-Dose Oral Dantrolene Sodium on Hepatic Function Jung Yoon Kim, MD, Sewoong Chun, MD, Moon Suk Bang, MD, PhD, Hyung-Ik Shin, MD, PhD, Shi-Uk Lee, MD, PhD ABSTRACT. Kim JY,
More informationIndications and Outcomes of Endoscopic CO 2 Laser Cricopharyngeal Myotomy
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Indications and Outcomes of Endoscopic CO 2 Laser Cricopharyngeal Myotomy Jennifer L. Bergeron, MD; Dinesh
More informationPeople normally swallow hundreds of times a day to eat
Evaluation and Management of Swallowing Disorders EXPERTOPINION By Joseph Spiegel, MD, Maurits Boon, MD, and Steven Mandel, MD Among other causes, dysphagia may be the presenting sign of several neurologic
More informationVideofluoroscopy quantification of laryngotracheal aspiration outcome in traumatic brain injury-related oropharyngeal dysphagia
06. ORIGINAL ROSA TERRÉ 9/2/07 12:30 Página 7 1130-0108/2007/99/1/7-12 REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS Copyright 2007 ARÁN EDICIONES, S. L. REV ESP ENFERM DIG (Madrid) Vol. 99. N. 1, pp. 7-12,
More informationAnterior Cervical Fusion: What is the Effect on Swallow Function?
Anterior Cervical Fusion: What is the Effect on Swallow Function? Rebecca L. Gould, MSC, CCC-SLP, BRS-S rebec26050@aol.com (561) 833-2090 www.med-speech.com STATE OF THE ART EVALUATION Anterior Cervical
More informationMULTIPLE reports have. Prediction of Aspiration in Patients With Newly Diagnosed Untreated Advanced Head and Neck Cancer ORIGINAL ARTICLE
ORIGINAL ARTICLE Prediction of Aspiration in Patients With Newly Diagnosed Untreated Advanced Head and Neck Cancer Arie Rosen, MD; Thomas H. Rhee, MD; Rene Kaufman, MS, CCC-SLP Objectives: To determine
More informationReview of dysphagia in poststroke
Review of dysphagia in poststroke patients Danielle Thompson, Speech and Language Therapist Northwick Park Hospital With acknowledgement to Mary McFarlane, Principal Speech and Language Therapist, Acute
More informationInjection of botulinum toxin for the treatment of post-laryngectomy pharyngoesophageal spasm-related disorders
ENT Ann R Coll Surg Engl 215; 97: 58 512 doi 1.138/rcsann.215.11 Injection of botulinum toxin for the treatment of post-laryngectomy pharyngoesophageal spasm-related disorders KA Lightbody 1, MD Wilkie
More informationLong-Term Bowel Symptoms Following Corrective Surgery
HIRSCHSPRUNG'S DISEASE Samuel Nurko MD MPH Center for Motility and Functional Gastrointestinal Disorders Children s Hospital Medical Center, Boston Ma Long-Term Bowel Symptoms Following Corrective Surgery
More informationPost-Prandial Trouble! KPA 2017 Nutrition pre-congress case Presentation Dr. Esther Kimani. Facilitator- Dr. A. Laving. 25/04/2017
Post-Prandial Trouble! KPA 2017 Nutrition pre-congress case Presentation Dr. Esther Kimani. Facilitator- Dr. A. Laving. 25/04/2017 Biodata. Name- I.M.M. Age-6 years Gender- female Referred to the Paediatric
More informationOriginal Article. Effect of the reclining position in patients after oral tumor surgery
J Med Dent Sci 2011; 58: 69-77 Original Article Effect of the reclining position in patients after oral tumor surgery Yoshiko Umeda 1), Shinya Mikushi 1), Teruo Amagasa 2), Ken Omura 3) and Hiroshi Uematsu
More informationBOTULINUM TOXIN AND INTRATHECAL BACLOFEN. Spencer Cotterell DO Mercy Rehabilitation Hospital June 30, 2018
BOTULINUM TOXIN AND INTRATHECAL BACLOFEN Spencer Cotterell DO Mercy Rehabilitation Hospital June 30, 2018 INJECTABLES MEDICAL MANAGEMENT OF SPASTICITY Leonard, J In: Botulinum toxin: 2009 A protein and
More informationCharacteristics of Dysphagia in Older Patients Evaluated at a Tertiary Center
The Laryngoscope VC 2014 The American Laryngological, Rhinological and Otological Society, Inc. Characteristics of Dysphagia in Older Patients Evaluated at a Tertiary Center Pelin Kocdor, MD; Eric R. Siegel,
More informationA Multidisciplinary Approach to Esophageal Dysphagia: Role of the SLP. Darlene Graner, M.A., CCC-SLP, BRS-S Sharon Burton, M.D.
A Multidisciplinary Approach to Esophageal Dysphagia: Role of the SLP Darlene Graner, M.A., CCC-SLP, BRS-S Sharon Burton, M.D. What is the role of the SLP? Historically SLPs the preferred providers for
More informationClinical Policy Title: Electrical stimulation for oropharyngeal dysphagia
Clinical Policy Title: Electrical stimulation for oropharyngeal dysphagia Clinical Policy Number: 09.01.03 Effective Date: September 1, 2013 Initial Review Date: May 15, 2013 Most Recent Review Date: May
More informationEsophageal Manometry. John M. Wo, M.D. October 1, 2009
Esophageal Manometry John M. Wo, M.D. October 1, 2009 Esophageal Manometry Anatomy and physiology of the esophagus Conventional esophageal manometry High resolution esophageal manometry (Pressure Topography)
More informationCase Report. Annals of Rehabilitation Medicine INTRODUCTION
Case Report Ann Rehabil Med 2013;37(3):438-442 pissn: 2234-0645 eissn: 2234-0653 http://dx.doi.org/10.5535/arm.2013.37.3.438 Annals of Rehabilitation Medicine Traumatic Atlanto-Occipital Dislocation Presenting
More informationClare Gaduzo BSc RMN Registered Aesthetics Practitioner (qualified with Medics Direct)
Clare Gaduzo BSc RMN Registered Aesthetics Practitioner (qualified with Medics Direct) 07935567067 cjg.aesthetics@yahoo.co.uk www.cjgaesthetics.co.uk http://www.facebook.com/cjgaesthetics @CJGAesthetics
More informationNormal and Abnormal Oral and Pharyngeal Swallow. Complications.
ESPEN Congress Gothenburg 2011 Assessment and treatment of dysphagia What is the evidence? Normal and Abnormal Oral and Pharyngeal Swallow. Complications. Pere Clavé Educational Session. Assessment and
More informationLaterality of pharyngeal bolus passage in Wallenberg s syndrome patients with dysphagia
J Med Dent Sci 2007; 54: 147 157 Original Article Laterality of pharyngeal bolus passage in Wallenberg s syndrome patients with dysphagia Shinya Mikushi 1, Eiichi Saitoh 2, Haruka Tohara 1, Mikoto Baba
More informationSWALLOWING DIFFICULTIES IN HD
Nutrition, eating and swallowing needs, challenges and solutions Workshop SWALLOWING DIFFICULTIES IN HD Angela Nuzzi Speech and Language Pathologist (SLP) EHDN Language Coordinator - Italy The role of
More information9/18/2015. Disclosures. Objectives. Dysphagia Sherri Ekobena PA-C. I have no relevant financial interests to disclose I have no conflicts of interest
Dysphagia Sherri Ekobena PA-C Disclosures I have no relevant financial interests to disclose I have no conflicts of interest Objectives Define what dysphagia is Define types of dysphagia Define studies
More informationHigh Resolution Manometry: A new perspective on esophageal motility disorders. Chris Andrews & Bill Paterson
High Resolution Manometry: A new perspective on esophageal motility disorders Chris Andrews & Bill Paterson CDDW/CASL Meeting Session: CanMEDS Roles Covered in this Session: Medical Expert (as Medical
More informationRECOMMENDATIONS & UPDATES IN THE MANAGEMENT OF POST- STROKE DYSPHAGIA
RECOMMENDATIONS & UPDATES IN THE MANAGEMENT OF POST- STROKE DYSPHAGIA Feeding in the Acute Stroke Period: - Early initiation of feeding is beneficial w/c decreases the risk of infections, improve survival
More informationTreatment Framework patient tracker
Treatment Framework patient tracker Utilize the BOTOX Treatment Framework when evaluating your Focal Spasticity patients to establish The right goals The right muscles/dose The right plan Use the following
More informationSwallowing disorder, aspiration: now what?
Swallowing disorder, aspiration: now what? Poster No.: C-0691 Congress: ECR 2015 Type: Educational Exhibit Authors: A. Kavka, M. Kysilko, M. Rocek; Prague/CZ Keywords: Swallowing disorders, Dynamic swallowing
More informationDiagnostic Delays in Spasmodic Dysphonia: A Call for Clinician Education
Diagnostic Delays in Spasmodic Dysphonia: A Call for Clinician Education Francis X. Creighton, Harvard University Edie Hapner, Emory University Adam Klein, Emory University Ami Rosen, Emory University
More informationSYNCOPE. Sanjay P. Singh, MD Chairman & Professor, Department of Neurology. Syncope
SYNCOPE Sanjay P. Singh, MD Chairman & Professor, Department of Neurology. Syncope Syncope is a clinical syndrome characterized by transient loss of consciousness (TLOC) and postural tone that is most
More informationSteven Frachtman, M.D. Division of Gastroenterology/Hepatology August 18, 2011
Steven Frachtman, M.D. Division of Gastroenterology/Hepatology August 18, 2011 Review normal esophageal anatomy and physiology Classifications of esophageal motility disorders Clinical features/diagnosis/management
More informationOesophageal Disorders
Oesophageal Disorders Anatomy Upper sphincter Oesophageal body Diaphragm Lower sphincter Gastric Cardia Symptoms Of Oesophageal Disorders Dysphagia Odynophagia Heartburn Atypical Chest Pain Regurgitation
More informationCONCETTI GENERALI SULLE DISFAGIE DI ORIGINE ESOFAGEA
LA DISFAGIA ESOFAGEA Pavia, 12.1.217 CONCETTI GENERALI SULLE DISFAGIE DI ORIGINE ESOFAGEA Michele Di Stefano Clinica Medica 1 Fondazione IRCCS Policlinico S.Matteo Università di Pavia Pavia PHARYNGOESOPHAGEAL
More informationJNM Journal of Neurogastroenterology and Motility
JNM Journal of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol. 20 No. 1 January, 2014 pissn: 2093-0879 eissn: 2093-0887 http://dx.doi.org/10.5056/jnm.2014.20.1.74 Original Article Utilizing
More informationManagement of dysphagia in MS
Management of dysphagia in MS Marta Renom Speech and Language Therapist CEM-CAT (UNeR) Barcelona INTRODUCTION Normal swallowing Dual function: transporting / protecting airway oral phase pharyngeal phase
More informationDavid Markowitz, MD. Physicians and Surgeons
Esophageal Motility David Markowitz, MD Columbia University, College of Columbia University, College of Physicians and Surgeons Alimentary Tract Motility Propulsion Movement of food and endogenous secretions
More informationMYOBLOC and Cervical Dystonia A Patient s Guide
MYOBLOC and Cervical Dystonia A Patient s Guide MYOBLOC (rimabotulinumtoxinb) Injection is indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position
More information«Einschluckstörungen»
18. Fortbildungskurs der SGG Brunnen 20.04.2018 «Einschluckstörungen» Troubles de la déglutition Swallowing disorders Dr Valérie Schweizer Unité de Phoniatrie Service ORL et chirurgie cervicofaciale CHUV
More informationBOTULINUM TOXIN THERAPY FOR CERVICOGENIC HEADACHE AND NECK PAIN
BOTULINUM TOXIN THERAPY FOR CERVICOGENIC HEADACHE AND NECK PAIN Dr. Laxman Bahroo Director; Botulinum Toxin Clinic Director; Neurology Residency Program Associate Professor of Neurology Objectives Discuss
More informationDYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex)
DYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex) CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about Dysport. It does not contain all
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia
More informationA CURIOUS CASE OF HYPERTENSIVE LES. Erez Hasnis Department of Gastroenterology Rambam Health Care Campus
A CURIOUS CASE OF HYPERTENSIVE LES Erez Hasnis Department of Gastroenterology Rambam Health Care Campus CASE DESCRIPTION 63yo, F, single, attending nurse. PMH includes T2DM (Sitagliptin/Metformin), Hyperlipidemia
More informationPrediction of Dysphagia Severity: An Investigation of the Dysphagia Patterns in Patients with Lateral Medullary Infarction
ORIGINAL ARTICLE Prediction of Dysphagia Severity: An Investigation of the Dysphagia Patterns in Patients with Lateral Medullary Infarction Fumiko Oshima 1, Megumi Yokozeki 2, Masashi Hamanaka 1, Keisuke
More informationDYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex)
DYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex) CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about Dysport. It does not contain all
More informationTreatment With Botulinum Toxin Type B for Upper-Limb Spasticity
103 Treatment With Botulinum Toxin Type B for Upper-Limb Spasticity Allison Brashear, MD, Anita L. McAfee, OTR, Elizabeth R. Kuhn, RN, Walter T. Ambrosius, PhD ABSTRACT. Brashear A, McAfee AL, Kuhn ER,
More informationLaryngeal Conservation
Laryngeal Conservation Sarah Rodriguez, MD Faculty Advisor: Shawn Newlands, MD, PhD The University of Texas Medical Branch Department of Otolaryngolgy Grand Rounds Presentation February 2005 Introduction
More informationBotulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia
The Journal of Laryngology & Otology (2008), 122, 52 56. # 2007 JLO (1984) Limited doi:10.1017/s0022215107007852 Printed in the United Kingdom First published online 1 May 2007 Main Article Botulinum toxin
More informationVideofluoroscopic Assessment of Patients with Dysphagia: Pharyngeal Retention Is a Predictive Factor for Aspiration
Edith Eisenhuber 1 Wolfgang Schima Ewald Schober Peter Pokieser Alfred Stadler Martina Scharitzer Elisabeth Oschatz Received June 4, 2001; accepted after revision September 28, 2001. Presented at the annual
More informationENDOSCOPIC MYOTOMY OF THE CRICOPHARYNGEAL MUSCLE WITH CO 2 LASER SURGERY
ENDOSCOPIC MYOTOMY OF THE CRICOPHARYNGEAL MUSCLE WITH CO 2 LASER SURGERY Robert P. Takes, MD, PhD, Frank J. A. van den Hoogen, MD, PhD, Henri A. M. Marres, MD, PhD Department of Otolaryngology/Head and
More informationSwallowing Function Defined by Videofluoroscopic Swallowing Studies after Anterior Cervical Discectomy and Fusion: a Prospective Study
ORIGINAL ARTICLE Rehabilitation & Sports Medicine https://doi.org/1.4/jkms.21.1.12.22 J Korean Med Sci 21; 1: 22-225 Swallowing Function Defined by Videofluoroscopic Swallowing Studies after Anterior Cervical
More informationWhen Eating Becomes A Challenge Dysphagia
When Eating Becomes A Challenge Dysphagia 1. DYSPHAGIA, WHAT IS IT? 2. IMPLICATIONS 3. ASSESSMENT 4. COMPENSATORY SWALLOWING AND EXERCISES 5. DIET TEXTURE ADJUSTMENTS Swallowing Dysfunction = Dysphagia
More informationMyogenic Control. Esophageal Motility. Enteric Nervous System. Alimentary Tract Motility. Determinants of GI Tract Motility.
Myogenic Control Esophageal Motility David Markowitz, MD Columbia University, College of Physicians and Surgeons Basic Electrical Rythym: intrinsic rhythmic fluctuation of smooth muscle membrane potential
More information